Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: Practical guidelines and current issues

American Journal of Clinical Pathology

Volumn 129, Issue 2, 2008, Pages 252-262

  Chang, Fuju ^a   Deere, Harriet ^a   Mahadeva, Ula ^a   George, Simi ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Esophagus; Histopathology; Neoadjuvant chemoradiotherapy; Residual carcinoma; Tumor regression grading

Indexed keywords

ADJUVANT CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW; ADJUVANT THERAPY; CARCINOMA; ESOPHAGUS TUMOR; LABORATORY DIAGNOSIS; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME;

CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; HUMANS; NEOPLASM, RESIDUAL; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY, ADJUVANT; SPECIMEN HANDLING; TREATMENT OUTCOME;

EID: 40449133028     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/CCR3QN4874YJDJJ7     Document Type: Review

References (48)

1. Jemal A, Murray T, Ward W, et al. Cancer statistics. CA Cancer J Clin. 2005;55:10-30.
2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-2252.
3. Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376-385.
4. Hagen JA, DeMeester SR, Peters JH, et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234:520-530.
5. Muller JM, Erasmi H, Stelzner M, et al. Surgical therapy of oesophageal carcinoma. Br J Surg. 1990;77:845-857.
6. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-2053.
7. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol. 2006;13:12-30.
8. Leichman L, Steiger Z, Seydel HG, et al. Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach. J Clin Oncol. 1984;2:75-79.
9. Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 1993;11:1118-1123.
10. Bosset J F, Gignoux M, Triboulet J P, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-167.
11. Kelsen D P, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979-1984.
12. Coia LR, Minsky BD, Berkey BA, et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. J Clin Oncol. 2000;18:455-462.
13. Stein H, Sendler A, Ulrich F, et al. Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am. 2000;80:659-682.
14. Heath EI, Burtness BA, Heitmiller R F, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol. 2000;18:868-876.
15. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-313.
16. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. Cancer. 2001;91:2165-2174.
17. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727-1734.
18. Meluch AA, Greco FA, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer; final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J. 2003;9:251-260.
19. Gebski V, Burmeister B, Smithers BM, at el. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226-234.
20. Greil R, Stein HJ. Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer [letter]? Lancet Oncol. 2007;8:189-190.
21. Schneider BJ, Urba SG. Preoperative chemoradiation for the treatment of locoregional esophageal cancer: the standard of care? Semin Radiat Oncol. 2007;17:45-52.
22. Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy: systematic review. Radiology. 2005;236:841-851.
23. Dunne B, Reynolds J V, Mulligan E, et al. A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. J Clin Pathol. 2001;54:841-845.
24. Brucher BL, Stein HJ, Zimmermann F, et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol. 2004;30:963-971.
25. Brucher BL, Becker K, Lordick F, et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer. 2006;106:2119-2127.
26. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684-692.
27. Malaisrie SC, Hofstetter WL, Correa AM, et al. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006;107:967-974.
28. Korst RJ, Kansler AL, Port JL, et al. Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma. Ann Thorac Surg. 2006;82:480-485.
29. de Manzoni G, Pedrazzani C, Pasini F, et al. Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol. 2007;95:261-266.
30. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma; clinicopathologic correlations. Cancer. 1994;73:2680-2686.
31. Hornick JL, Farraye FA, Odze RD. Prevalence and significance of prominent mucin pools in the esophagus post neoadjuvant chemoradiotherapy for Barrett's-associated adenocarcinoma. Am J Surg Pathol. 2006;30:28-35.
32. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355.
33. Swisher SG, Hofstetter W, Wu TT, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005;241:810-820.
34. Wu TT, Chirieac LR, Abraham SC, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007;31:58-64.
35. Wang KL, Yang Q, Cleary KR, et al. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation. Cancer. 2006;107:1467-1474.
36. Hermann RM, Horstmann O, Haller F, et al. Histomorphological tumor regression grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score to use? Dis Esophagus. 2006;19:329-334.
37. MacGuill M, Mulligan E, Ravi N, et al. Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer. Dis Esophagus. 2006;19:273-276.
38. Sobin LH, Wittekind CH, International Union Against Cancer, eds. TNM Classification of Malignant Tumours. 5th ed. Baltimore, MD: Wiley-Liss, 1997.
39. Ibrahim NB. Guidelines for handling oesophageal biopsies and resection specimens and their reporting. J Clin Pathol. 2000;53:89-94.
40. Stein HJ, Feith M, Siewert JR. Cancer of the esophagogastric junction. Surg Oncol. 2000;9:35-41.
41. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457-1459.
42. Forshaw MJ, Gossage JA, Mason RC. Neoadjuvant chemotherapy for oesophageal cancer: the need for accurate response prediction and evaluation. Surgeon. 2005;3:373-382, 422.
43. Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus. 2006;19:425-432.
44. Wieder HA, Brücher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900-908.
45. Heeren PA, Kloppenberg F W, Hollema H, et al. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res. 2004;24:2579-2583.
46. Schneider S, Uchida K, Brabender J, et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg. 2005;200:336-344.
47. Kaur T, Khanduja KL, Kaushik T, et al. P53, COX-2, iNOS protein expression changes and their relationship with antioxidant enzymes in surgically and multi-modality treated esophageal carcinoma patients. J Chemother. 2006;18:74-84.
48. Wu X, Gu J, Wu TT, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006;24:3789-3798.